![](https://endpts.com/wp-content/uploads/2021/08/Marianne-De-Backer-Jeffrey-Hatfield-tile-scaled.jpg)
Marianne De Backer (L) and Jeff Hatfield
Bayer nabs star biotech Vividion with a $2B buyout and an ‘arms-length’ pact, pulling a partner out of the IPO conga line
Vividion is canceling that IPO it filed. Instead of following the industry-wide migration to Nasdaq, the biotech that has captured considerable attention for its …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.